Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment

Lars Olson, Christian Humpel

To cite this version:

HAL Id: hal-00547646
https://hal.archives-ouvertes.fr/hal-00547646
Submitted on 17 Dec 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment

Lars Olson, Christian Humpel

PII: S0531-5565(09)00208-3
DOI: 10.1016/j.exger.2009.10.011
Reference: EXG 8663

To appear in: Experimental Gerontology

Received Date: 2 June 2009
Revised Date: 13 October 2009
Accepted Date: 15 October 2009

Please cite this article as: Olson, L., Humpel, C., Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment, Experimental Gerontology (2009), doi: 10.1016/j.exger.2009.10.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Growth factors and cytokines/chemokines
as surrogate biomarkers in cerebrospinal fluid and blood
for diagnosing Alzheimer’s disease and mild cognitive impairment

Lars Olson¹ and Christian Humpel ²

¹ Department of Neuroscience, Karolinska Institutet, Sweden
² Department of General and Social Psychiatry, Innsbruck Medical University, Austria

To whom correspondence should be addressed:

Dr. Christian Humpel, Department of Psychiatry and Psychotherapy,
Anichstr. 35, A-6020 Innsbruck, Austria.
Phone: +43-512-504-23712; Fax: +43-512-504-23713
E-mail: christian.humpel@i-med.ac.at
Abstract:

Alzheimer's disease (AD) is a severe chronic neurodegenerative disorder of the brain. A probable diagnosis of AD can be obtained by cerebrospinal fluid levels of 3 biomarkers: beta-amyloid (1-42), total tau and phospho-tau-181. Researchers are interested in finding additional biomarkers in CSF to improve the specificity and sensitivity of diagnosis, including also other forms of dementia, such as mild cognitive impairment (MCI). In addition, less invasive diagnostic methods using blood or blood-derived cells are being investigated. This mini-review (in concert with the other reviews of this special issue) summarizes the usefulness of growth factors and cytokines/chemokines as putative surrogate biomarkers for diagnosing AD and MCI in CSF and blood. Briefly, the expression levels of growth factors and cytokines/chemokines are very heterogeneous, indicating the pathological diversity of these diseases. At present, no single growth factor or cytokine alone stands out as a useful biomarker for diagnosing AD or MCI. However, the combined "patients profile signature" of several selected growth factors and/or cytokines/chemokines may allow to diagnose AD and MCI with higher selectively and specificity.

Key words: cerebrospinal fluid, blood, plasma, Alzheimer, diagnosis.
The life expectancy of humans has markedly increased within the last 100 years. As age is the main risk factor for Alzheimer’s disease (AD), the number of patients suffering from AD, and mixed forms of dementia will increase within the next 50 years. It is expected that there will be about 80 million AD patients worldwide in 2050. The establishment of reliable diagnostic surrogate markers for AD and measures to monitor disease progression is essential in order to evaluate novel treatments to counteract and/or delay symptoms in AD and to allow initiation of therapeutic interventions as early as possible. A valid and easily accessible diagnostic procedure should be the basis for the treatment.

*Dagnosis of Alzheimer’s disease and other forms of dementia*

AD is morphologically characterized by extracellular beta-amyloid plaque deposition, intraneuronal tau pathology, neuronal cell death, vascular dysfunction and inflammatory processes. Diagnosis requires both clinical assessment of the disease and post mortem detection of beta-amyloid plaques and tau-pathology. A probable diagnosis of AD can be established with a confidence of >90%, based on clinical criteria, including medical history, physical examination, laboratory tests, neuroimaging and neuropsychological evaluation. Accurate, early diagnosis of AD is still difficult because early symptoms of the disease are shared by a variety of disorders, reflecting common neuropathological features. The diagnosis of mixed forms of dementia, such as vascular dementia, frontotemporal lobe dementia or Lewy body dementia, is even more difficult.

The search for biomarkers becomes extremely important, due the large expected increase in dementia and AD patients within the next 50 years. It will be necessary to find "biomarkers of aging" and "biomarkers of disease". While a "biomarker of aging" may allow to follow up individuals over several years, a "biomarker of disease" will directly reflect the stage of the disease process (for details on diagnosis see Sprott as well as Cedazo-Minguez and Bengt Winblad; both this special issue of EXG). Briefly, we need to distinguish between biomarkers (1) that add to diagnostic certainty in the setting of a clinical evaluation, (2) those that can be used in lieu of a clinical evaluation, and (3) those that can be used to track disease progression at a specific stage. Although the
same biomarker could in theory be used in all these settings, most do not perform evenly across them. In addition, some biomarkers are more reasonably thought about as "risk factors" rather than "true disease" markers. In order for a diagnostic biomarker to be useful, certain criteria need to be met (Humpel and Marksteiner, 2009). (1) The biomarker should reflect some basic pathophysiological processes, and detect a fundamental feature of the disease with high sensitivity and specificity. (2) The biomarker should be specific for the disease compared with related disorders. (3) The biomarker should not reflect symptomatology of disorder. (4) The biomarker can be measured repeatedly over time and should be reproducible. (5) The biomarker should be measured in noninvasive easy-to-perform tests. (6) The biomarker should not cause harm to the individual being assessed. (7) The biomarker should be reliable in many testing environments/labs. (8) Validation by pathological diagnosis as gold standard should verify the set up of a biomarker in a specific disease. This mini-review (in concert with the other reviews in this special issue) will give an overview on the measurement of growth factors and cytokines/chemokines in CSF and blood. It will be shown, that all mentioned factors show a very high heterogeneity between the disease groups, and so far none of these biomarkers will meet all criteria for being a good biomarker.

**Growth factors in Alzheimer's disease**

One characteristic feature of AD pathology is death of basal forebrain cholinergic neurons and vascular damage. Nerve growth factor (NGF) is the most potent growth factor able to counteract cell death of cholinergic neurons in vitro and in vivo (Thoenen and Barde 1980; Levi-Montalcini 1987). While NGF dysfunction has been suggested in the development of AD, NGF knockout mice have not shown clear cognitive deficits. Nevertheless, NGF has been considered a candidate for treating AD and purified NGF was infused in some AD patients (Olson et al. 1992). And recently genetically engineered skin cells secreting NGF were transplanted into the nBM of Alzheimer patients by Tuszyński and colleagues (2005). Interestingly, NGF is up-regulated in brains (Fahnestock et al. 2001) and CSF (Hock et al. 2000) of AD patients, while the high-affinity NGF receptor trkA is down-regulated (Mufson et al. 2004). Furthermore, vascular endothelial growth factor (VEGF) is increased (Fukumura et al. 2001; Tarkowski et al. 2002), resulting in enhanced microvascular density in developing AD. Other growth factors may also contribute to AD pathology
and/or be dysregulated. Platelet-derived growth factor (PDGF) has been found to up-regulate amyloid-precursor-protein in hippocampus by inducing secretases (Gianni et al. 2003; Zambrano et al. 2004; Lim et al. 2007). Insulin-like growth factor-I (IGF-I) regulates beta-amyloid levels and displays protective effects against beta-amyloid toxicity (Carro et al. 2002; Aguado-Llera et al. 2005). Fibroblast growth factor-2 (FGF-2) shares binding sites with beta-amyloid fibrils on heparan sulfate from cerebral cortex (Lindahl et al. 1999) and plays a role in beta-amyloid toxicity (Cantara et al. 2005). Finally, members of the transforming growth factor-β (TGF-β) family interact with beta-amyloid, contributing to its toxicity or constituting a risk for cerebral beta-amyloid angiopathy (Hashimoto et al. 2005 and 2006).

_Inflammation and Alzheimer's disease_

Inflammation may constitute an important trigger of neurodegeneration during aging (“Inflammaging”) (Franceschi et al. 2001) and anti-inflammatory drugs may delay AD (Perry et al. 1995; Moore and O’Banion 2002). Chronic release of pro-inflammatory cytokines, such as interleukin-1β or tumor necrosis factor-α suggests roles in inflammation, pathology, and neuronal dysfunction associated with AD (Perry et al. 1995; Grammas and Ovase 2002). These inflammatory processes include activation of microglia and subsequent neuroinflammatory processes (Gonzalez-Scarano and Baltuch 1999). However, it is not clear if inflammation is merely a possibly aggravating result of beta-amyloid dysregulation (Moore and O’Banion 2002) or a primary cause of AD. Perivascular small vessel inflammation is another kehy feaure of AD, and it is well known that endothelial cells respond strongly to inflammatory stimuli (Moser, et al. 2004), especially involving production of reactive oxygen species (Iadecola 2004).

_A. GROWTH FACTORS_

Growth factors are proteins, which support the survival of cells of the central and peripheral nervous system, play a role in the development of the brain, stimulate axonal growth and regulate the growth of different kinds of cells in the brain and periphery. In many cases the same growth factor and corresponding receptor signaling system may thus serve a number of different functions in the body,
Nerve growth factor (NGF) is the most potent factor providing trophic support of cholinergic neurons in the basal forebrain. These cholinergic neurons degenerate early in AD, possibly due to compromised retrograde transport of NGF to the cell bodies of origin in the basal nucleus of Meynert and septum. NGF has been found to be increased in CSF of AD patients (Table 1A; Blasko et al., 2006; Hock et al., 2000; Marksteiner et al., 2008). Interestingly, the increase of NGF was specific for AD compared to healthy controls and was dependent on the extent of neurodegeneration as expressed by the phospho-tau181/beta-amyloid ratio (1-42) (Blasko et al., 2006). Although NGF data alone did not reveal a significant difference, the comparison of NGF in AD patients having a phospho-tau181/beta-amyloid ratio >10 with healthy control subjects (ratio <6) revealed a significant difference (Blasko et al., 2006). This might suggest that NGF accumulates in neurodegeneration only at a certain stage of the disease.

Several other growth factors have been measured in CSF or plasma, however, the data are very divergent between the different groups (Table 1A).

- **Hepatocyte growth factor** (HGF) is a paracrine cellular growth, motility and morphogenic factor and plays a major role in embryonic organ development, in adult organ regeneration and in wound healing.

- **Vascular endothelial growth factor** (VEGF) is an important growth factor, regulating angiogenesis in the nervous system.

- **Brain-derived neurotrophic factor** (BDNF; Barde, 1990) belongs to the family of neurotrophins. It serves very general plastic functions in the adult brain and is strictly upregulated in response to locally increased neuronal activity (Galloway et al., 2008). Of note, it has been reported that women have higher plasma BDNF levels than men, and that decreased plasma BDNF levels have been suggested to correlate with impaired memory and general cognitive function in aging women but not men (Komulainen et al., 2008).

- **Glial cell line-derived neurotrophic factor** (GDNF) stimulates the survival of several neurons, such as e.g. dopaminergic neurons and motorneurons.
• *Fibroblast growth factor-2 (FGF-2, bFGF)* belongs to a family of heparin-binding growth factors involved in angiogenesis, wound healing, and embryonic development.

• *Transforming growth factor-beta-1 (TGFβ-1)* plays a role in cellular proliferation and differentiation of a broad range of cells.

• *Insulin-like growth factor (IGFs)* are polypeptides with a marked sequence homology to insulin, playing an important role in cell-cell communication. Insulin-like growth factor binding protein-6 (IGFBP-6) controls the distribution, function and activity of insulin-like growth factors.

• *Epidermal growth factor (EGF)* stimulates the proliferation of various epidermal and epithelial cells, inhibits gastric acid secretion and is involved in wound healing.

• *Angiopoietin (ANG-2)* binds to the endothelial cell specific receptor Tie2 and promotes angiogenesis, sprouting and tube formation and the formation of new blood vessels.

• *Platelet-derived growth factor-BB (PDGF-BB)* is mitogenic for cells of mesenchymal origin.

• *Progranulin* is a glycoprotein growth factor involved in the regulation of multiple processes including tumorigenesis, wound repair, development and inflammation.

In summary, consensus is lacking regarding possible changes of the levels of several different growth factor in CSF and plasma in AD. However, NGF levels in CSF seem to be consistently increased in at least certain stages of AD. The consistency of NGF changes adds weight to a role of NGF in AD pathology, particularly when compared to the variable results seen with most other studied growth factors.

**B: CYTOKINES AND CHEMOKINES**

*Cytokines* comprise a large diverse family of proteins, peptides or glycoproteins that are used extensively in cellular communication. Historically, the term cytokine was
used to refer to immune modulating agents. Cytokines are now classified as lymphokines, interleukines and chemokines, based on their function and action on cellular targets. The term interleukin was initially used for cytokines targeting leukocytes. Chemokines are a family of small cytokines mediating chemoattraction (chemotaxis) between cells. Some chemokines are considered pro-inflammatory and can be induced during an immune response to recruit cells of the immune system to a site of infection, while others are considered homeostatic and are involved in controlling the migration of cells during normal processes of tissue maintenance or development. Interleukin-8 (CXCL8) is the only chemokine originally named an interleukin.

*Nomenclature of chemokines:* The C-C chemokines have two adjacent cysteines near their amino terminus. An example of a C-C chemokine is monocyte chemoattractant protein-1 (MCP-1 or CCL2) or CCL5 (RANTES). The two N-terminal cysteines of C-X-C chemokines are separated by one amino acid. An example of a C-X-C chemokine is interleukin-8 (IL-8, CXCL8). Other groups of chemokines are the C chemokines (e.g. lymphotactins) and the CX3C chemokines (e.g. fractalkine).

*Cytokines*

Different cytokines have been measured in CSF, plasma or serum (see Table 1B), such as interleukin-1α and -1β, interleukin-6 (IL-6), -10 (IL-10), -11 (IL-11), -18 (IL-18) and tumor-necrosis factor alpha (TNF-α, or TNFSF2) or macrophage migration inhibitory factor (MIF). As shown in Table 1B, the measurements are very divergent between the different groups. However, the combination of several chemokines in plasma (e.g. MIP1δ, MIP4 and RANTES; Marksteiner et al., 2009) may allow to diagnose AD and MCI (see Table 2).

*Colony-stimulating factors (CoSIF)*

Three members belong to the CoSF and have been measured in CSF and plasma (table 1B):

- Granulocyte colony-stimulating factor (G-CSF, or CSF-3) stimulates the bone marrow to produce granulocytes and stem cells and stimulates survival,
proliferation, differentiation and function of mature and neutrophil precursors and white blood cells.

- Macrophage colony stimulating factor (M-CSF, CSF-1) regulates proliferation, differentiation and survival of blood monocytes, tissue macrophages and progenitor cells.
- Interleukin-3 (IL-3 or multipotential colony-stimulating factor, Multi-CSF) is a hematopoietic growth factor that promotes the survival, differentiation and proliferation of megakaryocyte, granulocyte-macrophage, erythroid, eosinophil, basophil and mast cell progenitors and enhances thrombopoiesis, phagocytosis and cellular cytotoxicity and plays a role in immune defense.

**Chemokines**

Several chemokines have been measured in CSF or plasma, however, measurements are very divergent between the different groups (Table 1B): CCL2 (monocyte chemoattractant protein-1, MCP-1), CCL5 (RANTES), CCL7 (MCP-3), CCL15 (MIP-1-δ, macrophage inflammatory protein-18, MIP-5), CCL18 (MIP-4, macrophage inflammatory protein-4 or PARC) and CXCL8 (IL-8, interleukin-8). These chemokines are chemotactic or chemoattractant for monocytes and T-cells and other cell types and play an active role in recruiting cells cells into inflammatory sites.

**Culture of PBMCs and stimulated release**

To increase the specificity and sensitivity for biomarker search, isolated blood cells can be used to explore differential release of cytokines in AD compared to controls. The stimulation of cultured of peripheral blood mononuclear cells (PBMC) has been performed, and especially lipopolysaccharide (LPS) or phytohaemagglutinin (PHA) or also beta-amyloid seem to be very potent. In LPS stimulated PBMCs enhanced release of different cytokines (e.g. IL-2, TNF-α) has been reported in AD patients (Tan et al., 2007; Bergman et al., 2002; Kassner et al., 2008; Guerreiro et al., 2007; Kaplin et al., 2008), a decrease of IL-1β and IL-10 in severely demented patients (Sala et al., 2003; Bergman et al., 2002), while no effect on IL-6 release was found (Magaki et al., 2006). In PHA-stimulated cultures of PBMC from patients with MCI a
markedly enhanced secretion of IL-6 and a less pronounced enhanced secretion of IL-10 and IL-8, but not of TNFα or IL-1β, was found (Magaki et al., 2006). A significant decrease in IL-10 production was found in PBMCs after stimulation with beta-amyloid (Speciale et al., 2007).

To further explore differential release of cytokines/chemokines/growth factors from PBMCs we isolated in our lab PBMCs from 9 controls, 37 AD, 20 MCI and 11 depressive patients (Table 3). After stimulation with 4 µg/ml phytohemagglutinin-L (PHA) for 24hr in culture, the levels of biomarkers (interleukins-1α, -3, -11, EGF, G-CSF and MCP-3) were measured in the supernatants by Searchlight mutiplex ELISA (Marksteiner et al., 2009) or commercial single ELISA (IL-6, BioLegend). Statistical analysis was performed by one way ANOVA with a subsequent Dunnet posthoc test where p<0.05 was significant. Our novel data show that no changes were observed for IL-1α, IL-6, G-CSF and MCP-3 release. However, IL-3 and EGF release were significantly enhanced in MCI but not in the other groups, while IL-11 was significantly decreased in MCI but not in other groups (Table 3). When calculating the ratio EGF/IL-11 MCI patients could be differentiated from the other groups with high significance (Table 3). Our data suggest that the PHA-induced release of EGF and IL-11 from PBMCs may allow to diagnose MCI with high significance.

**Summary**

In summary, CSF and plasma levels of cytokines and chemokines are very heterogenous in different studies, and changes point to inflammatory reactions in AD. The striking differences between published studies may partly be due to true variations during the course of AD, for instance with respect to inflammatory and immune events. Needless to say, other explanations, including methodological differences between groups are also possible. Thus the mean levels of an individual biomarker may vary between serum, EDTA-plasma, citrate plasma and heparin plasma by a factor 20. Different commercial ELISA systems may led to different levels of the biomarkers, depending on the sensitivity and specificity of the used antibodies. An antibody may detect full length forms or spliced forms or precursor forms. Moreover, some biomarkers may show enhanced binding capacities to plasma/serum proteins, and only a pre-treatment may release the soluble forms. The stability of the biomarkers may vary and freezing and thawing may influence the
biochemical biomarker properties. Platelets serve as one storage compartment for several of the measured proteins and differences in platelet stability or perturbation may cause markedly different results. Finally, the ethnicity of patients may have an effect on protein levels as well. Thus, in summary, controlled standardized procedures to measure biomarkers in blood must be established to in order to better compare data from different centers. While more studies are needed to clarify these issues, a combined pattern of several cytokines/chemokines and/or their ratios may become of value in the diagnosis of AD and MCI using blood samples.

**CONCLUSIONS**

The expression levels of growth factors and cytokines/chemokines in CSF and blood of AD patients are very heterogenous, indicating pathological diversity of AD. In CSF only NGF seems to be significantly enhanced, probably reflecting reactions to the ongoing neurodegenerative processes in AD. Inflammatory cytokines and chemokines are differentially regulated, pointing to inflammatory events in AD. At present, no single growth factor or cytokine stands out as a useful biomarker for diagnosing AD or MCI. However, the combined "patients profile signature" of selected growth factors (e.g. EGF) and cytokines/chemokines (e.g. IL-11, RANTES, MIP-1\(\beta\), MIP4) may provide a diagnostic tool with high selectivity and specificity in AD and MCI by the use of blood samples.
Acknowledgements: This study was supported by the Austrian Science Funds (L429-B05). We want to thank Prof. Josef Marksteiner (Klagenfurt, Austria) and Prof. Elisabeth Weiss (Innsbruck, Austria) for blood collection and diagnosis and help with the study.
REFERENCES


Table 1A: Growth factors in cerebrospinal fluid and blood in dementia

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>increased</th>
<th>decreased</th>
<th>unchanged</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nerve growth factor</td>
<td>CSF (AD)</td>
<td></td>
<td></td>
<td>Blasko et al., 2006; Hock et al., 2000; Marksteiner et al., 2008</td>
</tr>
<tr>
<td>Hepatocyte growth factor</td>
<td>CSF (AD)</td>
<td>CSF (AD)</td>
<td></td>
<td>Tsuboi et al., 2003; Blasko et al., 2006</td>
</tr>
<tr>
<td>Vascular endothelial growth factor</td>
<td>CSF (AD)</td>
<td>CSF (AD)</td>
<td></td>
<td>Tsuboi et al., 2003; Blasko et al., 2006</td>
</tr>
<tr>
<td>Brain-derived neurotrophic factor</td>
<td>P (women)</td>
<td></td>
<td>CSF (AD)</td>
<td>Komulainen et al., 2008</td>
</tr>
<tr>
<td>Glial cell line-derived neurotrophic factor</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td>CSF (AD)</td>
<td>Blasko et al., 2006; Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Fibroblast growth factor-2</td>
<td></td>
<td></td>
<td>CSF (AD)</td>
<td>Blasko et al., 2006; Zetterberg et al., 2003</td>
</tr>
<tr>
<td>Transforming growth factor-1ß</td>
<td>CSF+P (AD)</td>
<td>S (AD)</td>
<td>CSF+S (AD)</td>
<td>Blasko et al., 2006; Zetterberg et al., 2003; Malaguarnera et al., 2006; Rodriguez et al., 2007; Mocali et al., 2004; de Servi et al., 2002</td>
</tr>
<tr>
<td>Insulin-like growth factor binding protein</td>
<td>P (AD)</td>
<td></td>
<td></td>
<td>Ray et al., 2007</td>
</tr>
<tr>
<td>Epidermal growth factor</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Angiopoietin-2</td>
<td>P (AD)</td>
<td></td>
<td>P (AD)</td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Platelet-derived growth factor-BB</td>
<td>P (AD)</td>
<td></td>
<td>P (AD)</td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Progranulin</td>
<td>CSF+P</td>
<td></td>
<td></td>
<td>Ghidoni et al., 2009</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; FTLD, frontotemporal lobe dementia; P, plasma; S, serum. Note that sometimes the same biomarkers has been found to be increased or decreased or unchanged reflecting the heterogeneity of the disease.
Table 1B: Cytokines and chemokines in cerebrospinal fluid and blood in dementia

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>increased</th>
<th>decreased</th>
<th>unchanged</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interleukin-1α</td>
<td>P (AD)</td>
<td>P (AD, MCI)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Interleukin-1β</td>
<td>S (AD)</td>
<td>P (AD, vD)</td>
<td></td>
<td>Angelopoulos et al., 2008; Kong et al., 2002</td>
</tr>
<tr>
<td>Interleukin-6</td>
<td>CSF</td>
<td>P (AD, FTLD, vD)</td>
<td>Schuitemaker et al., 2008; Galimberti et al., 2008; Angelopoulos et al., 2008; Dik et al., 2005; Bergman et al., 2002; Kog et al., 2002; Bermejo et al., 2008; Baranowska-Bik et al., 2008; Zuliani et al., 2007</td>
<td></td>
</tr>
<tr>
<td>Interleukin-10</td>
<td></td>
<td>P (AD, vD)</td>
<td></td>
<td>Angelopoulos et al., 2008</td>
</tr>
<tr>
<td>Interleukin-11</td>
<td>CSF+P</td>
<td>P (AD, MCI)</td>
<td></td>
<td>Galimberti et al., 2008; Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Interleukin-18</td>
<td>P (AD,vD)</td>
<td>P(AD)</td>
<td></td>
<td>Lindberg et al., 2005; Malaguarnera et al., 2006</td>
</tr>
<tr>
<td>Tumor necrosis factor-α</td>
<td>P (Ce)</td>
<td>P (AD)</td>
<td>P+S (AD, vD)</td>
<td>Bergman et al., 2002; Kong et al., 2002; Angelopoulos et al., 2008; Ray et al., 2007; Marksteiner et al., 2009; Bruunsgaard et al., 1999</td>
</tr>
<tr>
<td>Granulocyte-colony stimulating factor = CSF-3</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Macrophage-colony stimulating factor = CSF-1</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009; Kong et al., 2009</td>
</tr>
<tr>
<td>Interleukin-3 Multi-colony stimulating factor</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>CCL2 = Monocyte chemoattractant protein-1</td>
<td>S (AD, MCI)</td>
<td>CSF (AD)</td>
<td></td>
<td>Blasko et al., 2006; Galimberti et al., 2006</td>
</tr>
<tr>
<td>CCL5 = RANTES</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>CCL7 = Monocyte chemoattractant protein-3</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>CCL15 = Macrophage inflammatory protein-16</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>CCL18 = Macrophage inflammatory protein-4</td>
<td>P (AD, MCI)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>CXCL8 = Interleukin-8</td>
<td>P (AD)</td>
<td>P (AD)</td>
<td></td>
<td>Ray et al., 2007; Marksteiner et al., 2009</td>
</tr>
<tr>
<td>Macrophage migration inhibitory factor (MIF)</td>
<td>CSF (MCI, AD)</td>
<td></td>
<td></td>
<td>Popp et al., 2009</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimers disease; CSF, cerebrospinal fluid; Ce, centenarians; FTLD, frontotemporal lobe dementia; MCI, mild cognitive impairment; P, plasma; S, serum; vD, vascular dementia. Note that
sometimes the same biomarkers has been found to be increased or decreased or unchanged reflecting the heterogeneity of the disease.
Table 2: Plasma derived biomarkers

<table>
<thead>
<tr>
<th></th>
<th>control</th>
<th>MCI</th>
<th>AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>19</td>
<td>44</td>
<td>96</td>
</tr>
<tr>
<td>MIP1δ</td>
<td>3,890±510</td>
<td>4,784±334 ns</td>
<td>5,212±260 *</td>
</tr>
<tr>
<td>MIP4</td>
<td>65,900±9,300</td>
<td>90,942±7,275 *</td>
<td>81,716±5,720 ns</td>
</tr>
<tr>
<td>RANTES</td>
<td>9,823±2,418</td>
<td>20,824±4,581 *</td>
<td>23,280±3,724 *</td>
</tr>
</tbody>
</table>

Values are taken from Marksteiner et al., Neurobiology of Aging, 2009 in press; values are given as mean±SEM pg/ml, as measured by Multiplex Searchlight ELISAs. MCI, mild cognitive impairment; AD Alzheimer's disease. *p<0.05, ns not significant. MIP, macrophage inflammatory protein, RANTES, regulated upon activation, normal T cell expressed and secreted.
Table 3: Stimulated release of cytokines and growth factors from peripheral blood mononuclear cells of patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD) or depression compared to healthy controls.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>MCI</th>
<th>AD</th>
<th>Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>68±4</td>
<td>71±1</td>
<td>76±1</td>
<td>70±2</td>
</tr>
<tr>
<td>MSSE</td>
<td>28.4±0.3</td>
<td>27.0±0.4</td>
<td>18.6±0.1***</td>
<td>28.0±0.2</td>
</tr>
<tr>
<td>n</td>
<td>9</td>
<td>20</td>
<td>37</td>
<td>11</td>
</tr>
<tr>
<td>IL-1α</td>
<td>11.3±4.1</td>
<td>13.3±1.5</td>
<td>9.0±0.8</td>
<td>11.2±2.6</td>
</tr>
<tr>
<td>IL-3</td>
<td>0.13±0.09</td>
<td>0.42±0.05*</td>
<td>0.18±0.03</td>
<td>0.15±0.08</td>
</tr>
<tr>
<td>IL-6</td>
<td>1.38±0.40</td>
<td>1.02±0.14</td>
<td>1.01±0.12</td>
<td>0.91±0.17</td>
</tr>
<tr>
<td>IL-11</td>
<td>5.14±1.15</td>
<td>1.90±0.14**</td>
<td>3.93±0.45</td>
<td>3.95±1.02</td>
</tr>
<tr>
<td>EGF</td>
<td>1.22±0.28</td>
<td>1.91±0.15*</td>
<td>1.17±0.09</td>
<td>0.94±0.13</td>
</tr>
<tr>
<td>G-CSF</td>
<td>124.7±29</td>
<td>97.5±11</td>
<td>88.7±8</td>
<td>100.5±15</td>
</tr>
<tr>
<td>MCP-3</td>
<td>0.64±0.24</td>
<td>0.47±0.04</td>
<td>0.52±0.06</td>
<td>0.52±0.08</td>
</tr>
<tr>
<td>Ratio EGF/IL-11</td>
<td>0.31±0.08</td>
<td>1.14±0.14***</td>
<td>0.43±0.04</td>
<td>0.37±0.07</td>
</tr>
</tbody>
</table>

EDTA blood was collected from patients, centrifuged on a Biocoll gradient, the PBMCs were isolated and an aliquot cultured in medium with 4 µg/ml phytohemagglutinin-L for 24 hr, and then the levels of biomarkers were measured in the supernatants by Searchlight multiplex ELISA or commercial single ELISA (IL-6). Values are given as mean±SEM ng/ml per 1 mg cells per 24 hr. Statistical analysis was performed by one way ANOVA with a subsequent Dunnet posthoc test (* p<0.05; ** p<0.01; *** p<0.001). EGF, epidermal growth factor; G-CSF, granulocyte-colony stimulating factor; IL, interleukins, MCP, monocyte chemoattractant protein.